Cinzia Ortega

3.0k total citations
52 papers, 1.0k citations indexed

About

Cinzia Ortega is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Cinzia Ortega has authored 52 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Cinzia Ortega's work include Renal cell carcinoma treatment (17 papers), Prostate Cancer Treatment and Research (13 papers) and Cancer Genomics and Diagnostics (10 papers). Cinzia Ortega is often cited by papers focused on Renal cell carcinoma treatment (17 papers), Prostate Cancer Treatment and Research (13 papers) and Cancer Genomics and Diagnostics (10 papers). Cinzia Ortega collaborates with scholars based in Italy, Ukraine and United States. Cinzia Ortega's co-authors include Daniele Regge, Camillo Porta, Stefano Cirillo, Massimo Petracchini, P. Gabriele, Maria Cristina Bona, Teresa Gallo, Lorenza Scotti, Giovanni Grignani and Antonio Manca and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Cinzia Ortega

52 papers receiving 994 citations

Peers

Cinzia Ortega

PRM

ONCOL

SURGE

Kathryn Richert-Boe United States

Sukhbinder Dhesy‐Thind Canada

Réza Elaidi France

Vincent Trudeau Canada

Jennifer LaFemina United States

Stefania Salvagni Italy

Constance Thibault France

Hideki Ishida Japan

Deniz Tural Türkiye

Kathryn Richert-Boe United States

Cinzia Ortega

393 ×0.8

PRM

531 ×1.2

ONCOL

224 ×0.7

140 ×0.5

SURGE

137 ×0.8

Citations per year, relative to Cinzia Ortega Cinzia Ortega (= 1×) peers Kathryn Richert-Boe

Countries citing papers authored by Cinzia Ortega

Since Specialization

Citations

This map shows the geographic impact of Cinzia Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cinzia Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cinzia Ortega more than expected).

Fields of papers citing papers by Cinzia Ortega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cinzia Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cinzia Ortega. The network helps show where Cinzia Ortega may publish in the future.

Co-authorship network of co-authors of Cinzia Ortega

This figure shows the co-authorship network connecting the top 25 collaborators of Cinzia Ortega. A scholar is included among the top collaborators of Cinzia Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cinzia Ortega. Cinzia Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fasola, Gianpiero, Giacomo Pelizzari, Francesco Grossi, et al.. (2023). Implementation of Precision Oncology in Clinical Practice: Results of a National Survey for Health Care Professionals. The Oncologist. 28(6). e324–e330. 3 indexed citations

Giannatempo, Patrizia, Valentina Guadalupi, Laura Marandino, et al.. (2023). 2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial. Annals of Oncology. 34. S1205–S1205. 1 indexed citations

Mennitto, Alessia, Elena Verzoni, Francesco Cognetti, et al.. (2021). Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Review of Clinical Pharmacology. 14(2). 261–268. 7 indexed citations

Indini, Alice, C. Aschele, Luigi Cavanna, et al.. (2020). Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. European Journal of Cancer. 132. 17–23. 73 indexed citations

Grassi, Paolo, Ludovic Doucet, Viktor Grünwald, et al.. (2017). Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology. 92(5). 269–275. 3 indexed citations

Giorgi, Ugo De, Giuseppe Procopio, Annalisa Guida, et al.. (2017). Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP). Annals of Oncology. 28. v320–v321. 3 indexed citations

Caffo, Orazio, Elisa Biasco, Gaetano Facchini, et al.. (2016). Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. Annals of Oncology. 27. vi252–vi252. 2 indexed citations

Facchini, Gaetano, Orazio Caffo, Cinzia Ortega, et al.. (2016). Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. Frontiers in Pharmacology. 7. 123–123. 32 indexed citations

Cavaliere, Carla, Orazio Caffo, Cinzia Ortega, et al.. (2016). Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival.. Journal of Clinical Oncology. 34(2_suppl). 219–219. 1 indexed citations

10.

Bertoldo, Francesco, Franco Silvestris, Toni Ibrahim, et al.. (2014). Targeting bone metastatic cancer: Role of the mTOR pathway. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1845(2). 248–254. 26 indexed citations

11.

Procopio, Giuseppe, Roberto Sabbatini, Camillo Porta, et al.. (2012). Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy. 12(8). 1089–1096. 5 indexed citations

12.

Masini, Cristina, Roberto Sabbatini, Camillo Porta, et al.. (2012). Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. British Journal of Urology. 110(5). 692–698. 36 indexed citations

13.

Porta, Camillo, Roberto Sabbatini, Giuseppe Procopio, et al.. (2012). Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Review of Anticancer Therapy. 12(12). 1571–1577. 30 indexed citations

14.

Santini, Daniele, Gaia Schiavon, Bruno Vincenzi, et al.. (2011). Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. PLoS ONE. 6(4). e19234–e19234. 136 indexed citations

15.

Ravasio, Roberto, Cinzia Ortega, Roberto Sabbatini, & Camillo Porta. (2011). Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy. Clinical Drug Investigation. 31(7). 507–517. 11 indexed citations

16.

Anselmetti, Giovanni Carlo, Antonio Manca, Gabriele Chiara, et al.. (2011). Painful Pathologic Fracture of the Humerus: Percutaneous Osteoplasty With Bone Marrow Nails Under Hybrid Computed Tomography and Fluoroscopic Guidance. Journal of Vascular and Interventional Radiology. 22(7). 1031–1034. 10 indexed citations

17.

Lorenzo, Giuseppe Di, Carlo Buonerba, Piera Federico, et al.. (2010). Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. European Urology. 58(6). 906–911. 44 indexed citations

18.

Cirillo, Stefano, Massimo Petracchini, Lorenza Scotti, et al.. (2008). Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. European Radiology. 19(3). 761–769. 147 indexed citations

19.

Carlo, R. Di, R. Faggiuolo, Giampiero Muccioli, et al.. (1994). Prognostic significance of prolactin receptor on overall survival of patients with early breast cancer: a long-term retrospective analysis. The Breast. 3(3). 147–150. 2 indexed citations

20.

Dogliotti, Luigi, et al.. (1992). Three Yearsʼ Experience with Tropisetron in the Control of Nausea and Vomiting in Cisplatin-Treated Patients. Drugs. 43(Supplement 3). 6–10. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact